Nektar Therapeutics buy me8
Start price
07.08.23
/
0%
€0.95
Target price
07.08.24
-
Performance (%)
-29.26%
End price
19.08.23
€0.67
Summary
This prediction ended on 19.08.23 with a price of €0.67. The prediction for Nektar Therapeutics disappointed with a performance of -29.26%. This prediction was marked as speculative and is excluded from me8's performance statistics.Nektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Nektar Therapeutics | 2.566% | 2.566% |
| iShares Core DAX® | 2.831% | 1.236% |
| iShares Nasdaq 100 | 2.918% | 0.640% |
| iShares Nikkei 225® | 2.007% | -2.135% |
| iShares S&P 500 | 2.257% | 0.451% |
According to me8 what are the pros and cons of Nektar Therapeutics for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Good culture
Capable Management
Cons
Few uniques
Comments by me8 for this prediction
In the thread Nektar Therapeutics diskutieren
Buy Nektar Therapeutics
In the thread Trading Nektar Therapeutics
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.